|
Patent landscape, scope, and claims summary: |
Patent Landscape and Claims Analysis of US Patent 5,667,787
What does US Patent 5,667,787 cover?
US Patent 5,667,787, issued on September 16, 1997, to Eli Lilly and Company, addresses methods of modulating the activity of serotonergic receptors, specifically 5HT receptors. The patent claims include compositions and methods for the use of compounds that act as antagonists or partial agonists to 5HT receptors for therapeutic applications, primarily in neuropsychiatric disorders.
Key claims:
- The patent claims the use of specific chemical compounds for modulating the 5HT receptor activity.
- It covers both the compounds themselves and their pharmaceutical compositions.
- Methods involve administering these compounds to treat conditions such as depression, anxiety, schizophrenia, and irritable bowel syndrome.
The claims are broad in scope concerning chemical structures, covering multiple classes of compounds with varying substitution patterns, thus providing substantial coverage over related molecules.
How has the patent landscape evolved since issuance?
Related Patents and Follow-up Filings
- The patent ecosystem surrounding 5HT receptor modulators is extensive, with multiple filings from Eli Lilly and other pharmaceutical entities.
- Several subsequent patents have claimed improvements, such as increased selectivity, improved pharmacokinetics, or alternative formulations.
- Notably, US Patent 6,962,885, filed in 1999, extends claims to more specific compounds with improved activity profiles.
- Patent applications focused on subtypes of 5HT receptors, such as 5HT3 and 5HT4, have been filed to carve niche protections relevant to targeted therapies.
Key patenting trends:
- Concentration on chemical modifications to enhance receptor selectivity.
- Emphasis on formulations facilitating administration routes.
- Efforts to extend patent life via continuation and divisionals, with filings extending into 2020s.
Patent expirations and implications
- Primary claims date to 1997; patent term extensions are unlikely as patents typically expire 20 years from filing.
- Expiration opens pathways for generics or biosimilars, increasing competition.
- For example, if any related patents (such as method claims) expire around 2017-2018, this broadens the landscape for alternative compounds.
Overlapping patents from competitors
- Pharmaceutical companies such as Johnson & Johnson and Novartis filed patents on similar receptor modulators, often with different chemical scaffolds targeting the same indication.
- These overlapping patents can create freedom-to-operate issues and influence R&D strategies.
What are the strengths and limitations of the patent claims?
Strengths:
- Broad chemical coverage: The claims encompass multiple chemical classes, providing a wide scope of protection.
- Relevance to multiple therapeutic areas: The claims support use in depression, anxiety, schizophrenia, and gastrointestinal disorders.
- Doctrine of equivalents: The language allows for some flexibility in claiming structurally similar compounds, expanding protection.
Limitations:
- Patent claims are limited to compounds active at 5HT receptors, which may face challenges if similar compounds target other pathways.
- Some claims may be vulnerable to challenges based on prior art, especially structural similarities to existing serotonergic agents.
- Patent citations and literature could limit enforceability if prior art uncovers similar compounds predating the patent.
Legal status and enforceability:
- The patent is enforceable until September 2017, unless subject to extension or litigation.
- Current legal status indicates it is inactive or expired, opening opportunities for generic development.
Critical considerations for stakeholders
- Innovation scope: The patent's broad claims on chemical structures could have been a barrier for competitors until expiry.
- Patent expiry: After expiration, companies can develop generic versions, potentially reducing prices.
- Research implications: The extensive patent landscape suggests ongoing innovation, but patent expiry exposes opportunities for new therapeutic agents targeting serotonergic pathways.
Key Takeaways
- US Patent 5,667,787 claims chemical compositions and methods related to serotonergic receptor modulation, focusing on therapeutic applications.
- Its broad claims contributed to early protection but are now expired, paving the way for generic entry.
- The patent landscape includes multiple follow-up patents focused on receptor subtypes and improved formulations.
- Overlaps with other patents from competitors can influence patent strategies and market entry.
- Legal challenges based on prior art and patent expiration are critical factors in strategic planning.
FAQs
Q1: Are the claims of US Patent 5,667,787 still enforceable?
No, the patent expired in 2017, making it unenforceable outside of any extension or legal disputes.
Q2: How does the patent landscape influence new drug development targeting 5HT receptors?
The broad initial patent provided protection for key chemical scaffolds, but filing new patents on improved selectivity or formulations remains common.
Q3: What are the implications for generic drug manufacturers?
Patent expiration allows generics to enter the market, increasing competition and potentially reducing prices for serotonergic treatments.
Q4: Can competitors develop drugs based on similar compounds after patent expiry?
Yes, unless they infringe on other active patents covering specific compounds, methods, or formulations still in force.
Q5: How do follow-up patents impact the original patent’s relevance?
Follow-up patents extend protection to new compounds, formulations, or methods, maintaining a competitive advantage even after the original patent expires.
References
- United States Patent and Trademark Office. (1997). US Patent 5,667,787.
- World Intellectual Property Organization. Patent Landscape Reports on Serotonergic Agents.
- Eli Lilly and Company Patent Files. (1997–2020). Publicly available patent documents.
- Johnson & Johnson Patent Portfolio on Serotonergic Receptor Drugs.
- Novartis Patent Applications Related to 5HT Receptor Modulation.
More… ↓
⤷ Start Trial
|
